

Substitute for form 1449A/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			
<b>Complete If Known</b>			
<b>Application Number</b>		10/516,757	
<b>Filing Date</b>		December 4, 2004	
<b>First Named Inventor</b>		Rabussay, Dietmar	
<b>Art Unit</b>		TBA	
<b>Examiner Name</b>		TBA	
Sheet	1	of	2
Attorney Docket No: GTI-1490-US			

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
1	3523907		08/11/1970	VRANCKEN et al	
2	5171568		12/15/1992	BURKE et al	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
3	WO 89/04669		06/01/1989	HOUGHTON et al	
4	WO 90/11089		10/04/1990	HOUGHTON et al	
5	WO 90/14436		11/29/1990	HOUGHTON et al	
6	WO 90/14837		12/13/1990	VAN NEST et al	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	7	BAER et al, "DNA Sequence and Expression of the B95-8 Epstein Barr Virus Genome," <i>Nature</i> 310:207-211 (1984)			
	8	CHEE et al, "Analysis of the protein-coding content of the sequence of human cytomegaloviruses strain AD169," <i>Curr Top Microbiol Immunol.</i> 154:125-169			
	9	DAVISON et al, "The complete DNA sequence of varicella-zoster virus," <i>J. Gen. Virol.</i> 67:1759-1816 (1986)			
	10	DOE et al, "Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans," <i>Eur. J. Immunol.</i> 24(10):2369-2376 (1994)			
	11	ERICKSON et al "Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis," <i>J. Immunol.</i> 151:4189-4199 (1993)			
	12	HOUGHTON et al, "Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease," <i>Hepatology</i> 14(2):381-388 (1991)			
	13	JEFFERY et al, "The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique," <i>Pharm Res.</i> 10(3):362-368 (1993)			
	14	KAWAOKA et al, "Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus," <i>Virology</i> 179:759-767 (1990)			
	15	MCGEOCH et al, "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type," <i>J. Gen. Virol.</i> 69:1531-1574 (1988)			
	16	MIZUSHIMA et al, "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> 18(17):5322 (1990)			
	17	MODROW et al, "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions," <i>J. Virology</i> 61:570-578 (1987)			
	18	MORIARTY et al, "Expression of the Hepatitis B Virus Surface Antigen Gene in Cell Culture by Using a Simian Virus 40 Vector," <i>Proc. Natl. Acad. Sci. (USA)</i> 78(4):2606-2610 (1981)			
	19	O'HAGAN et al, "Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles," <i>Vaccine</i> 11:965-969 (1993)			
	20	OGAWA et al, "A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid," <i>Chem. Pharm. Bull.</i> 36:1095-1103 (1988)			
	21	OTT et al, "MF-59—Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines," in POWELL et al, <i>Vaccine Design: The Subunit and Adjuvant Approach</i> Plenum Press, New York pp. 277-296 (1995)			
	22	REMINGTON <i>The Science and Practice of Pharmacy</i> , Mack Publishing Company, Easton, PA, 19 <sup>th</sup> Edition (1995)			

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use as many sheets as necessary)			
Sheet	2	of	2
<b>Attorney Docket No: GTI-1490-US</b>			

	<b>23</b>	VAN NEST et al, "Advanced adjuvant formulations for use with recombinant subunit vaccines," in BROWN et al, <i>Vaccines 92, Modern Approaches to New Vaccines</i> Cold Springs Harbor Laboratory Press pp. 57-62 (1992)	
	<b>24</b>	WEBSTER et al, "Antigenic variation among type A influenza viruses," p. 127-168. In: alese et al (ed.), <i>Genetics of influenza viruses</i> . Springer-Verlag, New York	

---

**EXAMINER****DATE CONSIDERED**